PMVP — PMV Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $90.03m
- -$113.03m
- 34
- 49
- 51
- 41
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 26.6 | 34.9 | 58.3 | 77 | 80.1 |
Operating Profit | -26.6 | -34.9 | -58.3 | -77 | -80.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -25.3 | -34.4 | -57.8 | -73.3 | -69 |
Provision for Income Taxes | |||||
Net Income After Taxes | -25.4 | -34.4 | -57.8 | -73.3 | -69 |
Net Income Before Extraordinary Items | |||||
Net Income | -25.4 | -34.4 | -57.8 | -73.3 | -69 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -25.4 | -34.4 | -57.8 | -73.3 | -69 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.59 | -0.769 | -1.28 | -1.61 | -1.44 |
Dividends per Share |